Trial Profile
A Randomized, Double-Blind,Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Sep 2021
Price :
$35
*
At a glance
- Drugs Bryostatin-1 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Neurotrope BioScience; Synaptogenix
- 30 Jul 2021 Results of pooled analysis from NTRP101-202 and NTRP101-203, presented at the Alzheimer's Association International Conference 2021.
- 26 Jul 2021 Results published in the Synaptogenix Media Release.
- 22 Jan 2020 According to a Neurotrope BioScience media release, company is planning to meet with the Food and Drug Administration to present the totality of the clinical program data for Bryostatin-1 (NTRP101-202 and NTRP101-203).